70 related articles for article (PubMed ID: 26471496)
1. Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival.
Jatoi A; Foster NR; Kalli KR; Vierkant RA; Zhang Z; Larson MC; Fridley B; Goode EL
BMC Cancer; 2015 Oct; 15():711. PubMed ID: 26471496
[TBL] [Abstract][Full Text] [Related]
2. The influence of reproductive and hormonal factors on ovarian cancer survival.
Nagle CM; Bain CJ; Green AC; Webb PM
Int J Gynecol Cancer; 2008; 18(3):407-13. PubMed ID: 17645507
[TBL] [Abstract][Full Text] [Related]
3. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.
Tworoger SS; Fairfield KM; Colditz GA; Rosner BA; Hankinson SE
Am J Epidemiol; 2007 Oct; 166(8):894-901. PubMed ID: 17656616
[TBL] [Abstract][Full Text] [Related]
4. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
5. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
[TBL] [Abstract][Full Text] [Related]
6. Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai Women's Health Study.
Huang Z; Gao Y; Wen W; Li H; Zheng W; Shu XO; Beeghly-Fadiel A
Int J Cancer; 2015 Aug; 137(3):607-14. PubMed ID: 25556333
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Persson IR
Gynecol Oncol; 2001 Dec; 83(3):575-85. PubMed ID: 11733975
[TBL] [Abstract][Full Text] [Related]
8. Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer.
Faber MT; Jensen A; Frederiksen K; Glud E; Høgdall E; Høgdall C; Blaakaer J; Kjaer SK
Cancer Causes Control; 2013 Dec; 24(12):2197-206. PubMed ID: 24077761
[TBL] [Abstract][Full Text] [Related]
9. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
10. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.
Modugno F; Ness RB; Allen GO; Schildkraut JM; Davis FG; Goodman MT
Am J Obstet Gynecol; 2004 Sep; 191(3):733-40. PubMed ID: 15467532
[TBL] [Abstract][Full Text] [Related]
12. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.
Jordan SJ; Green AC; Whiteman DC; Moore SP; Bain CJ; Gertig DM; Webb PM; ;
Int J Cancer; 2008 Apr; 122(7):1598-603. PubMed ID: 18058817
[TBL] [Abstract][Full Text] [Related]
13. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study.
Vessey M; Yeates D
Contraception; 2013 Dec; 88(6):678-83. PubMed ID: 24090961
[TBL] [Abstract][Full Text] [Related]
14. Oral contraceptive use and the risk of ovarian cancer. The Centers for Disease Control Cancer and Steroid Hormone Study.
JAMA; 1983 Mar; 249(12):1596-9. PubMed ID: 6338264
[TBL] [Abstract][Full Text] [Related]
15. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
17. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
Narod SA; Risch H; Moslehi R; Dørum A; Neuhausen S; Olsson H; Provencher D; Radice P; Evans G; Bishop S; Brunet JS; Ponder BA
N Engl J Med; 1998 Aug; 339(7):424-8. PubMed ID: 9700175
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
20. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception.
Bentzen JG; Forman JL; Pinborg A; Lidegaard Ø; Larsen EC; Friis-Hansen L; Johannsen TH; Nyboe Andersen A
Reprod Biomed Online; 2012 Dec; 25(6):612-9. PubMed ID: 23069740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]